Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of trastuzumab plus XELOX as first-line treatment for HER2-positive advanced or metastatic gastric cancer
2011-001231-23Phase 2Completed
- Sponsor
- Fundación para el Progreso de la Oncología en Cantabria
- Start
- Sep 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, capecitabine and oxaliplatin in gastric cancer (GC) and gastric adenocarcinoma, sponsored by Fundación para el Progreso de la Oncología en Cantabria. Primary endpoint: Overall survival. Started Sep 2011; status: completed.
02
Drugs
03
Conditions
gastric cancer (GC)gastric adenocarcinoma
Beyond the preview
Go deeper on 2011-001231-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001231-23.